Their results are corroborated by several clinical studies in LN patients and experimental studies in mice, which demonstrated that serum level of ANXA2-binding immunoglobins, as well as expression of glomerular ANXA2, is associated with active LN progression (Ka et al., 2006; Salle et al., 2016; Zhou et al., 2018; Tesch et al., 2020). The gene discussed is ANXA2; the disease is lobular neoplasia.